Xofluza, developed by Genentech, is an influenza antiviral medication. It works by inhibiting the cap-dependent endonuclease activity of the influenza virus polymerase acidic protein [1]. This mechanism is distinct from older influenza drugs that target the M2 protein or neuraminidase [2].
How does Xofluza work differently from other flu treatments?
Xofluza's mechanism of action targets the viral polymerase complex, specifically the cap-dependent endonuclease. This is a novel approach compared to older antivirals like oseltamivir (Tamiflu) and zanamivir (Relenza), which inhibit the neuraminidase enzyme [2]. By blocking the endonuclease, Xofluza prevents the virus from initiating RNA synthesis, thereby stopping viral replication [1].
When will Xofluza's patents expire?
Information on Xofluza's patent expiry is available on DrugPatentWatch.com [3]. Specific patent expiry dates can vary, and it is advisable to consult specialized resources for the most current details [3].
What is the difference between Xofluza and Tamiflu?
Xofluza and Tamiflu (oseltamivir) are both antiviral medications used to treat influenza, but they differ in their mechanism of action and dosing. Xofluza inhibits viral polymerase activity, while Tamiflu inhibits neuraminidase [1][2]. Xofluza is typically administered as a single oral dose, whereas Tamiflu is usually taken orally twice daily for five days [1][4].
What are the potential side effects of Xofluza?
Common side effects reported with Xofluza include diarrhea, bronchitis, nausea, and headache [1]. More serious potential adverse events, though rare, can include bronchospasm and facial swelling [1].
Can Xofluza be used to prevent the flu?
Xofluza is approved for the treatment of acute, uncomplicated influenza in individuals 12 years of age and older who have been symptomatic for no more than 48 hours [1]. It is not indicated for the prevention of influenza [1].
What clinical trials have been conducted for Xofluza?
Several clinical trials have evaluated Xofluza's efficacy and safety. Key studies include the PHLUORINE study, which assessed its use in treatment-naive adult patients, and the BLOCKBuster study, which examined its effectiveness in preventing influenza in household contacts of infected individuals [5]. Comparative studies have also been performed against oseltamivir [4].